Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering and a concurrent private placement, aiming to raise approximately $2.9 million in gross proceeds. The company announced the transactions on August 11, 2026, with the closing expected on or about August 14, 2026, subject to customary conditions.
Under the terms, Dyadic will issue 3,625,000 common shares at a price of $0.795 per share in the registered direct offering. In the private placement, the company will sell warrants to purchase an equal number of common shares at $0.005 per warrant, with an exercise price of $0.84 per share. The combined gross proceeds from both offerings are expected to total approximately $2.9 million.
The company intends to use the net proceeds, along with its existing cash, cash equivalents, restricted cash, and investment-grade securities, for working capital and general corporate purposes. This capital infusion is anticipated to support Dyadic’s ongoing research and development efforts and its commercialization strategies.
Dyadic Applied BioSolutions is a global biotechnology company focused on developing and commercializing scalable, non-animal protein production platforms. These platforms, including the proprietary Dapibus™ and C1 expression systems, are designed to address the growing global demand in the life sciences, food and nutrition, and bio-industrial markets. By leveraging these technologies, Dyadic aims to enable its customers to create more efficient, scalable, and sustainable products.
The significance of this financing lies in its potential to accelerate Dyadic’s mission of providing high-value proteins that reduce reliance on animal-derived products. The company’s non-animal protein platforms could play a crucial role in meeting future food and pharmaceutical needs sustainably, as global populations and environmental concerns rise.
Aegis Capital Corp. is serving as the exclusive placement agent for the offerings. For more details on the transaction, interested parties can refer to the full press release at https://ibn.fm/od7FJ.
Dyadic’s technology has the potential to disrupt traditional protein production by offering cost-effective and flexible manufacturing alternatives. The company’s C1 expression system, in particular, is known for its ability to produce high yields of proteins in fungal hosts, which could lower production costs and improve scalability compared to mammalian cell cultures.
As the global market for alternative proteins expands, Dyadic is positioning itself to capitalize on this trend. The proceeds from this offering will likely be allocated toward advancing its product pipeline and expanding its market reach. Investors and industry observers will be watching to see how this capital deployment affects the company’s growth trajectory in the coming quarters.
For more information about Dyadic International, visit their website at https://dyadic.com/.
